Recently, Fengxun Biotech announced the completion of the pre-A round of financing of 100 million yuan. New investment institutions introduced in this round include Neighbor Star Investment, Yueyin Medical Fund, and Jianggen Capital; old shareholders Junlian Capital, Hongfeng Investment, and Hanyuan Asset added additional investments at the same time. This round of funding will focus on promoting non-clinical development and registration of CAR-T pipelines in hematologic tumors and solid tumors, continuously improving the closed-loop technology platform for the entire internal CAR-T process driven by generative AI as the core, and supporting the layout of subsequent innovation pipelines.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.